br- we can always count on you to put the most negative slant on any available information.
The future of ponatinib is yet to be told. More sophisticated dosing schedules and combinations will undoubtedly develop so that patients can benefit from the power it has.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.